{
    "nct_id": "NCT00990613",
    "title": "A Phase 1, Fixed Sequence, Cross-Over Study To Investigate The Single Dose Pharmacokinetics Of A Dimebon (Latrepirdine) Transdermal Solution Relative To The Immediate Release Formulation In Older Adults",
    "status": "COMPLETED",
    "last_update_time": "2010-02-02",
    "description_brief": "To estimate the absorption, safety, and tolerability of a dimebon transdermal solution relative to the dimebon immediate release oral formulation.",
    "description_detailed": "N/A",
    "phase": [
        "PHASE1"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "N/A",
    "results": null,
    "target_category": "Cognitive enhancer",
    "drug": [
        "Dimebon (latrepirdine) \u2014 an orally active small\u2011molecule antihistamine investigated for cognition enhancement in Alzheimer\u2019s disease"
    ],
    "placebo": [],
    "explanation_target": [
        "Reason: The trial compares a dimebon (latrepirdine) transdermal solution vs immediate\u2011release formulation \u2014 the intervention is latrepirdine (Dimebon), a small\u2011molecule antihistamine originally repurposed and studied for its potential cognition\u2011enhancing/neuroprotective effects in Alzheimer\u2019s disease rather than as a biologic aimed at amyloid or tau. \ue200cite\ue202turn0search12\ue202turn0search4\ue201.",
        "Act: Key details extracted \u2014 drug name: dimebon (latrepirdine); drug type: small molecule (antihistamine/nootropic candidate); intended effect in AD trials: improve cognition/global function (cognitive enhancement), not a monoclonal antibody or vaccine targeting amyloid/tau. Late\u2011stage trials ultimately failed to show benefit in Phase 3. \ue200cite\ue202turn0search12\ue202turn0search1\ue202turn0search0\ue201.",
        "Reflect: Classification check \u2014 this is not a biologic, and it is not described as targeting core AD pathology via an anti\u2011amyloid or anti\u2011tau mechanism; rather it was developed as a nootropic/neuroprotective small molecule to improve cognition, so the appropriate category is \"Cognitive enhancer.\" The Phase 3 negative results and unclear mechanism are noted, but they do not change the intervention's class. \ue200cite\ue202turn0search1\ue202turn0search0\ue201.",
        "Web search results (sources used): 1) Latrepirdine (Dimebon) summary \u2014 small\u2011molecule antihistamine repurposed as a cognition enhancer/neuroprotective candidate. \ue200cite\ue202turn0search12\ue201. 2) Pfizer/Medivation Phase 3 (CONNECTION) press release describing Phase 3 negative results and endpoints (cognition measures such as ADAS\u2011cog, MMSE). \ue200cite\ue202turn0search1\ue201. 3) PubMed review/animal study noting dimebon effects and unclear mechanisms in AD models. \ue200cite\ue202turn0search0\ue201. 4) Preclinical work showing latrepirdine can modulate autophagy/mitochondrial function, consistent with proposed neuroprotective/cognition\u2011enhancing actions rather than a targeted anti\u2011amyloid biologic. \ue200cite\ue202turn0search4\ue202turn0search3\ue201."
    ],
    "agent_type": "M) Synaptic Plasticity/Neuroprotection",
    "explanation_agent": [
        "Reason: The intervention is latrepirdine (dimebon), an orally active small\u2011molecule antihistamine repurposed as a cognition\u2011enhancing/neuroprotective agent in AD rather than a biologic directed at amyloid or tau. \ue200cite\ue202turn0search2\ue202turn0search0\ue201",
        "Act: Extracted details \u2014 drug: dimebon (latrepirdine); drug type: small\u2011molecule antihistamine/nootropic candidate; proposed effects in AD: cognition enhancement and neuroprotection (mechanisms explored include modulation of mitochondria, autophagy and low\u2011affinity NMDA/H1 receptor effects), not an anti\u2011amyloid or anti\u2011tau therapeutic. \ue200cite\ue202turn0search5\ue202turn0search2\ue201",
        "Reflect: Given CADRO definitions, the trial\u2019s focus on cognitive enhancement and putative neuroprotective/synaptic effects maps best to M) Synaptic Plasticity/Neuroprotection. The compound\u2019s unclear, multi\u2011modal mechanisms (autophagy/mitochondrial hints) do not specifically target amyloid, tau, inflammation, vasculature, or other single CADRO categories, so M is the most appropriate single-category assignment. Phase\u20113 failures are noted but don\u2019t change the target class. \ue200cite\ue202turn0search3\ue202turn0search4\ue201",
        "Web search results (sources used): 1) Review: 'The rise and fall of Dimebon' (PubMed) \u2014 overview of origin, repurposing, unclear mechanism. \ue200cite\ue202turn0search2\ue201 2) Pfizer press release on Phase 3 CONNECTION results \u2014 dimebon did not meet primary endpoints. \ue200cite\ue202turn0search0\ue201 3) Pfizer/Medivation CONCERT Phase 3 results press release \u2014 negative trial when added to donepezil. \ue200cite\ue202turn0search3\ue201 4) Preclinical study showing latrepirdine enhances autophagy and reduces intracellular A\u03b2 in model systems. \ue200cite\ue202turn0search5\ue201 5) Additional Pfizer/Medivation trial summary and program context. \ue200cite\ue202turn0search4\ue201"
    ]
}